Not sure how much to read into that. Acadia stated their intent to setup in shop Switzerland to support pimavanserin back in their Sept 2015 quarterly.
During the first half of 2015, we licensed worldwide intellectual property rights related to pimavanserin in certain indications to ACADIAPharmaceuticals GmbH, our wholly-owned Swiss subsidiary. Our goals for the establishment of ACADIA Pharmaceuticals GmbH, and the licensing ofworldwide intellectual property rights for pimavanserin, include building a platform for long-term operational and financial efficiencies, including tax-relatedefficiencies.
NEU Price at posting:
$7.16 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)